Improving quality of life through innovations in urology.
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Initiates Part 2 of Phase 3...
on October 21, 2019
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Oct. 21, 2019-- Urovant Sciences […]
Read Latest Post -
Urovant Sciences Reports Positive Long-Term...
on September 24, 2019
Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms […]
Read Latest Post -
Urovant Sciences Parent Company, Roivant...
on September 6, 2019
Sumitomo Dainippon Pharma is expected to fully assume Roivant’s ownership interest of Urovant […]
Read Latest Post
Copyright 2018 © All Rights Reserved